« Back
Home /
Buparlisib

Buparlisib

Item no.	HY-70063-100mg
Manufacturer	MedChem Express
CASRN	944396-07-0
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 500 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lymphatic System Cancer
Type	Inhibitors
Specific against	other
Purity	99.90
Citations	[1]Burger MT, et al. Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. ACS Med Chem Lett. 2011 Aug 26;2(10):774-9.\|[2]Zheng Y, et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity. J Mol Med (Berl). 2012 Jun;90(6):695-706.\|[3]Ni J, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 Jul;22(7):723-6.\|[4]Liu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8(3):354-369. ACS Appl Mater Interfaces. 2019 Apr 3;11(13):12342-12356. \|Am J Transl Res. 2019 Sep 15;11(9):6055-6065.\|Anticancer Res. 2018 Jun;38(6):3375-3385.\|Autophagy. 2022 Jul;18(7):1551-1571.\|Biomed Pharmacother. 2024 Oct 16:180:117569.\|Biomedicines. 2022, 10(8), 1988.\|bioRxiv. 2022 Aug 02.\|bioRxiv. 2023 Aug 13.\|bioRxiv. 2023 Jul 24.\|bioRxiv. 2024 Dec 10:2024.12.09.627542.\|bioRxiv. 2025 February 23.\|BMC Anesthesiol. 2021 Aug 30;21(1):210.\|Brain Behav. 2018 Nov;8(11):e01123.\|Cancer Cell Int. 2020 Mar 18;20:86.\|Cancer Commun (Lond). 2022 Feb 18.\|Cancer Discov. 2018 Mar;8(3):354-369.\|Cancer Discov. 2019 Sep;9(9):1306-1323. \|Cancer Discov. 2020 Aug;10(8):1226-1239.\|Cancer Immunol Immunother. 2024 May 7;73(7):122.\|Cancer Lett. 2019 Jan;440-441:54-63.\|Cancer Res. 2022 Jul 27;CAN-22-0042.\|Cancers (Basel). 2022, 14(22), 5481\|Cancers (Basel). 2024 Aug 7;16(16):2785.\|Cell Commun Signal. 2019 May 15;17(1):44.\|Cell Rep. 2024 Apr 23;43(5):114132.\|Cell Syst. 2020 Jan 22;10(1):66-81.e11.\|Clin Med Insights Oncol. 2024 Oct 16:18:11795549241285387.\|Cold Spring Harb Mol Case Stud. 2020 Jun 12;6(3):a004853.\|Diabetologia. 2021 Feb 11.\|Endocrinology. 2023 Sep 13;bqad135.\|Eur J Pharmacol. 2023 May 2;175747.\|Gastroenterologie, Hepatologie und Endokrinologie. 2020 Oct.\|Harvard Medical School LINCS LIBRARY\|Hepatol Commun. 2019 Feb 5;3(3):423-436.\|In Vitro Cell Dev Biol Anim. 2021 May 5.\|J Cell Biol. 2020 Dec 7;219(12):e202001031.\|J Cell Biol. 2023 Sep 4;222(9):e202208150.\|J Clin Endocrinol Metab. 2021 Jan 1;106(1):e232-e246.\|J Endocr Soc. 2021 Jun 1.\|J Exp Med. 2023 Nov 6;220(11):e20211743.\|J Transl Med. 2024 Nov 7;22(1):1004.\|JCI Insight. 2024 Dec 20;9(24):e178535.\|Mol Carcinog. 2022 Apr 13.\|Mol Carcinog. 2024 Apr 17\|Molecules. 2020 Apr 23;25(8):1980.\|Nat Biomed Eng. 2018 Aug;2(8):578-588.\|Nat Cancer. 2024 Jul 11.\|Nat Commun. 2020 May 19;11(1):2487.\|Nat Commun. 2021 Jun 8;12(1):3444.\|Nat Commun. 2022 Sep 29;13(1):5723.\|Nat Med. 2016 Jul;22(7):723-6.\|Nature. 2018 Aug;560(7719):499-503.\|Nature. 2022 Dec;612(7940):555-563.\|Nature. 2024 Sep;633(8031):895-904.\|Oncogene. 2016 Jul 7;35(27):3607-12. \|Oncogene. 2022 Jan 20.\|Oncoimmunology. 2019 Mar 16;8(5):e1581556.\|Patent. US20160215053A1.\|Patent. US20210236501A1.\|PLoS One. 2016 Jan 28;11(1):e0147682. \|PLoS One. 2018 Jul 5;13(7):e0200014.\|Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9570-E9579. \|Programa de Doctorado en Biomedicina. 2020 Sep.\|Prostate. 2018 Feb;78(3):166-177.\|Research Square Print. 10 Jan 2023.\|Research Square Print. November 7th, 2022\|Sci Adv. 2022 Jan 21;8(3):eabh2635.\|Sci Rep. 2019 Jan 30;9(1):978.\|Sci Signal. 2019 May 28;12(583). pii: eaaw9450. \|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Sci Transl Med. 2023 Feb 22;15(684):eade1857.\|Science. 2025 Mar 14;387(6739):eadm9805.\|University of Gothenburg. 2023 Jun 27.\|World J Gastroenterol. 2023 Oct 28.\|Cell Rep. 2020 Sep 29;32(13):108196.
Smiles	FC(F)(C1=C(C2=CC(N3CCOCC3)=NC(N4CCOCC4)=N2)C=NC(N)=C1)F
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BKM120,NVP-BKM120
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; PI3K
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	410.39
Product Description	Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)\|H2O: < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis; PI3K/Akt/mTOR
Isoform	PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ; Vps34
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-70063-100mg-safety-datasheet.pdf